상처 봉합 및 첨단 상처 치료 시장 : 제품 유형, 상처 유형, 임상 용도, 제품 사용성, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Wound Closure & Advanced Wound Care Market is projected to grow by USD 32.51 billion at a CAGR of 8.04% by 2032.

Wound closure and advanced wound care are converging into a high-priority segment of healthcare delivery as surgical volumes, trauma care needs, diabetes, obesity, vascular disease, and population aging expand the clinical burden of acute and chronic wounds. The category spans sutures, staples, tissue adhesives, sealants, hemostats, negative pressure wound therapy, antimicrobial and foam dressings, hydrocolloids, alginates, collagen products, skin substitutes, and digital wound assessment tools.

Demand is supported by verified public-health trends: the WHO reports that more than 800 million adults were living with diabetes in 2022, while the United Nations projects that one in six people globally will be aged 65 or older by 2050. The International Diabetes Federation also identifies diabetic foot complications as a major cause of hospitalization and lower-limb amputation among people with diabetes. These trends raise the incidence of diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical-site complications, making evidence-based wound closure and advanced wound care central to cost control, patient outcomes, and hospital quality performance.

Transformative Shifts in the Wound Care Landscape

The wound closure and advanced wound care landscape is shifting from commodity wound covering toward outcome-driven wound healing. Clinicians increasingly prioritize moist wound healing, exudate control, infection prevention, tissue regeneration, scar minimization, and reduced time to closure. This is accelerating adoption of antimicrobial dressings, bioactive matrices, absorbable closure devices, topical skin adhesives, hemostatic agents, and negative pressure wound therapy across hospitals, ambulatory surgery centers, long-term care, and home healthcare.

A second shift is the move from episodic treatment to continuum-based wound management. Payers and providers are placing greater emphasis on preventing surgical-site infections, pressure injuries, amputations, and readmissions because these complications increase length of stay and downstream costs. Regulatory expectations for clinical evidence, biocompatibility, antimicrobial stewardship, usability, and post-market surveillance are also reshaping product development and commercialization strategies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler of wound closure and advanced wound care rather than a distant concept. AI-supported imaging can help estimate wound area, wound edge change, tissue type, exudate patterns, and healing trajectory from standardized photographs. In diabetic foot care and pressure injury prevention, predictive models can support earlier risk stratification by combining comorbidities, mobility, perfusion, nutrition, infection markers, and prior wound history.

The impact is cumulative across the care pathway: better triage, more consistent documentation, remote monitoring, supply planning, clinician education, and clinical decision support. However, AI adoption must align with FDA software-as-a-medical-device principles, EU medical-device and AI requirements, data privacy rules, bias testing, cybersecurity, and clinician oversight. The strongest use cases will augment, not replace, wound specialists by improving consistency, speed, and visibility across wound healing workflows.

Key Regional Insights

Asia-Pacific is gaining strategic importance because China, India, Japan, South Korea, and Australia combine large surgical populations with rising diabetes prevalence, aging demographics, and investment in hospital capacity. National health systems across the region are also expanding digital health, infection prevention, and chronic disease management programs, which supports demand for advanced dressings, negative pressure wound therapy, and telewound assessment. North America remains a benchmark for premium wound closure and advanced wound care technologies, supported by advanced reimbursement pathways, high procedure volumes, outpatient wound care centers, hospital quality programs, and strong adoption of negative pressure wound therapy, biologics, antimicrobial dressings, and digital assessment tools.

Latin America is expanding through private hospital networks, trauma care needs, and growing access to modern dressings, although affordability, public reimbursement variability, and uneven specialist access remain constraints. Europe is shaped by Medical Device Regulation compliance, health technology assessment, antimicrobial stewardship, sustainability expectations, and demand for cost-effective healing outcomes across aging populations. The Middle East is investing in specialty care, diabetes management infrastructure, and high-acuity hospital systems, while Africa presents long-term potential tied to trauma care, infection control, burn management, surgical access, and stronger procurement systems for essential and advanced wound care products.

Key Group Insights

ASEAN markets are advancing through hospital modernization, medical tourism, expanding middle-class access, and regional manufacturing, with demand strongest for affordable advanced dressings, antimicrobial products, surgical closure devices, and infection-control solutions. The GCC is prioritizing specialty wound clinics, diabetes care, high-quality hospital infrastructure, and digital health adoption, creating opportunities for negative pressure wound therapy, skin substitutes, advanced hemostats, and structured digital wound documentation.

The European Union is defined by MDR conformity, sustainability expectations, antimicrobial stewardship, and rigorous clinical evidence requirements that favor products with demonstrable healing, safety, and economic benefits. BRICS countries offer scale, domestic manufacturing momentum, and broad chronic disease burden, but pricing, procurement, and access strategies must be localized to public and private healthcare realities. G7 markets continue to set evidence, reimbursement, quality, and post-market surveillance standards for advanced wound care. NATO-related demand reinforces innovation in trauma closure, hemorrhage control, burn care, infection prevention, and field-ready wound management technologies that can support military and civilian emergency care systems.

Key Country Insights

The United States leads in premium wound technologies, outpatient wound centers, home health integration, and value-based attention to surgical-site infection reduction, while Canada emphasizes evidence-based procurement, clinical guideline alignment, and equitable access across provinces. Mexico and Brazil show rising demand through private healthcare expansion, trauma care requirements, and increasing chronic wound needs linked to diabetes and vascular disease. The United Kingdom, Germany, France, Italy, and Spain are shaped by aging populations, public reimbursement scrutiny, antimicrobial stewardship, and demand for demonstrable cost offsets across hospitals, community care, and long-term care settings.

Russia requires localized supply, distributor reliability, and procurement resilience amid complex market access conditions. China and India represent high-volume opportunities driven by diabetes, surgery, hospital expansion, and government attention to healthcare infrastructure, while Japan and South Korea favor quality, innovation, infection control, and aging-care solutions for acute and chronic wounds. Australia combines strong clinical standards with remote-care needs, creating demand for telewound support, durable advanced dressings, and care models that can connect urban specialty providers with rural and remote patients.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize products that prove faster healing, fewer infections, fewer dressing changes, lower complication risk, and reduced total cost of care. Clinical evidence should include real-world outcomes across diabetic foot ulcers, venous leg ulcers, pressure injuries, burns, surgical wounds, and traumatic wounds, with endpoints that matter to clinicians, payers, and procurement teams, including time to closure, infection rates, pain, ease of use, and resource utilization.

Commercial teams should tailor portfolios by site of care: operating rooms require reliable closure, hemostasis, sealants, and surgical efficiency; wound centers require regenerative, antimicrobial, and exudate-management solutions; long-term care requires pressure injury prevention and simplified protocols; home care requires ease of use, patient adherence, and remote documentation. Leaders should also invest in AI-ready image capture, interoperable data systems, sustainable materials, antimicrobial stewardship, clinician training, and regional manufacturing or dual-sourcing to reduce supply risk.

Research Methodology

This executive summary is developed from a structured secondary-research methodology using validated public-health, regulatory, clinical, and economic sources. Inputs include WHO, United Nations, CDC, FDA, European Commission, OECD, International Diabetes Federation, peer-reviewed wound care literature, hospital quality frameworks, clinical guidelines, and publicly available reimbursement and regulatory disclosures.

The analysis triangulates disease burden, surgical demand, chronic wound risk factors, technology adoption, reimbursement trends, regulatory requirements, and regional healthcare infrastructure. Market interpretation emphasizes verified directional evidence over unsupported claims, with careful distinction between established clinical practice, emerging digital tools, and future innovation pathways. Conclusion

Wound closure and advanced wound care are moving from product-based purchasing to outcomes-based wound management. The strongest opportunities are linked to aging populations, diabetes-related complications, surgical recovery, infection prevention, home-based care, and technologies that make healing measurable across acute and chronic wound settings.

Organizations that combine clinical evidence, AI-enabled documentation, regional access strategies, clinician education, and resilient supply chains will be best positioned to serve providers and patients. As healthcare systems seek lower complication rates, fewer avoidable admissions, and better resource utilization, advanced wound care will remain a critical pillar of surgical quality, chronic disease management, trauma care, and value-based healthcare delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Wound Closure & Advanced Wound Care Market, by Product Type

• 7.1. Traditional Wound Closure Devices
  • 7.1.1. Sutures
  • 7.1.2. Staples
  • 7.1.3. Mechanical Closure Devices
    • 7.1.3.1. Skin Closure Strips
    • 7.1.3.2. Zipper Closure Devices
    • 7.1.3.3. Retention Closure Devices
• 7.2. Advanced Wound Dressings
  • 7.2.1. Foam Dressings
  • 7.2.2. Hydrogel Dressings
  • 7.2.3. Film Dressings
  • 7.2.4. Collagen Dressings
  • 7.2.5. Antimicrobial Dressings
• 7.3. Hemostatic Agents And Sealants
• 7.4. Advanced Therapies
  • 7.4.1. Negative Pressure Wound Therapy Devices
  • 7.4.2. Oxygen Therapy Systems
  • 7.4.3. Electrical Stimulation Devices
  • 7.4.4. Ultrasound Therapy Devices
• 7.5. Biologics & Regenerative Products
  • 7.5.1. Skin Substitutes
    • 7.5.1.1. Allogeneic Skin Substitutes
    • 7.5.1.2. Xenogeneic Skin Substitutes
    • 7.5.1.3. Bioengineered Skin Substitutes
  • 7.5.2. Growth Factor Therapies
  • 7.5.3. Cell-Based Therapies

8. Wound Closure & Advanced Wound Care Market, by Wound Type

• 8.1. Chronic Wounds
• 8.2. Acute Wounds

9. Wound Closure & Advanced Wound Care Market, by Clinical Application

• 9.1. Surgical Wound Closure
• 9.2. Trauma Wound Management
• 9.3. Sports Injury Management
• 9.4. Reconstructive & Plastic Surgery
• 9.5. Burn Wound Management
• 9.6. Chronic Ulcer Management

10. Wound Closure & Advanced Wound Care Market, by Product Usability

• 10.1. Single-Use
• 10.2. Reusable

11. Wound Closure & Advanced Wound Care Market, by End User

• 11.1. Hospitals
• 11.2. Ambulatory Surgical Centers
• 11.3. Specialty Clinics
• 11.4. Home Healthcare Providers
• 11.5. Military & Veteran Care Facilities

12. Wound Closure & Advanced Wound Care Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Wound Closure & Advanced Wound Care Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Wound Closure & Advanced Wound Care Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Wound Closure & Advanced Wound Care Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Solventum Corporation
• 17.2. Smith & Nephew PLC
• 17.3. Molnlycke Health Care AB
• 17.4. Baxter International Inc.
• 17.5. Johnson & Johnson Services, Inc.
• 17.6. Convatec Limited
• 17.7. Paul Hartmann AG
• 17.8. Organogenesis Inc.
• 17.9. Medtronic PLC
• 17.10. Coloplast A/S
• 17.11. Medline Industries, Inc.
• 17.12. Laboratoires Urgo
• 17.13. Essity AB
• 17.14. Integra LifeSciences Corporation
• 17.15. MiMedx Group, Inc.
• 17.16. Lohmann & Rauscher GmbH & Co. KG
• 17.17. B. Braun SE
• 17.18. Nichiban Co., Ltd.
• 17.19. Zimmer Biomet Holdings, Inc.
• 17.20. Cardinal Health, Inc.
• 17.21. PolyNovo Limited
• 17.22. Advanced Medical Solutions Group PLC
• 17.23. Avery Dennison Corporation
• 17.24. BDK Industrial Products Ltd.
• 17.25. Biogennix, LLC
• 17.26. DermaRite Industries, LLC
• 17.27. Healogics, LLC
• 17.28. Lotus Surgicals by TI Medical
• 17.29. Plastod S.p.A